In a recently published open-label randomized controlled clinical trial,1 100 patients with mild to moderate COVID-19 were given either standard care in addition to 500 mg of Quercetin Phytosome per day or standard care with placebo for two weeks.

Patients with blood cancer have fewer antibodies after SARS-CoV-2 vaccination — but recent work shows that these antibodies seem to bind to viral spike protein more strongly than those in matched controls. Consistent with our understanding of affinity maturation, anti-spike IgG antibody levels and avidity increase with each SARS-CoV-2 vaccine dose in healthy individuals, and this correlates with in vitro virus neutralization3.

Anti-S IgG responses in 90% of participants who were seropositive for SARS-CoV-2 at baseine were boosted foowing a singe vaccination with 1 μg of LNP-nCoVsaRNA.Seroconversion rates were significanty higher than those we previousy reported. Removed sampes for binding and neutraising antibody: 1.0 μg foowed by 10.0 μg.

Our aim of the study was to develop and validate a simple scoring system to predict in-hospital mortality among patients with COVID-19 pneumonia within the first days of hospitalization, which was based mainly on different presenting symptoms, comorbidities, vital signs, and some laboratory data in addition to some local and affordable treatment options entered into the regression model. Predictors of severity and mortality in COVID-19 patients. Scoring systems for predicting mortality for severe patients with COVID-19.

At the seven day follow up, it was established that 45% more patients in the CUR-QUE group were clear of the COVID inflection, suggesting they were able to clear the virus significantly faster than the control group. In addition, it was observed that the acute symptoms initially observed had cleared in 40% of the CUR-QUE treated group at day seven, when compared to 16% of the control group. The study results suggest that the combined intakes of CUR-QUE may have therapeutic potential for treating the COVID-19 virus in patients at an early stage.

/ POP Biotechnologies, a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2 clinical trial of EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain antigen on the immunogenic liposomes. POP BIO is developing new vaccine product candidates and is seeking further collaborators around the SNAP technology to make use of the unique qualities of the vaccine platform technology.